Generic medicines are equivalent versions of branded medicines that can enter the market once patent and regulatory barriers allow.

In practice

Generic entry can reduce medicine prices and widen access, especially where public procurement systems negotiate at scale.

IP-services relevance

Health-service affordability depends on the timing of generic entry. Patent terms and data exclusivity settings can accelerate or delay that timing.

Examples

• A medicine becomes available at lower cost after patent expiry and generic approval.
• Data exclusivity delays market entry even after a key patent has expired.
• Public reimbursement agencies use generic competition to improve coverage.